Lv11
40 积分 2021-09-26 加入
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2
2个月前
已完结
EZH2 promotes proliferation and invasiveness of prostate cancer cells
2个月前
已完结
EZH1/2 as targets for cancer therapy
2个月前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
11个月前
已完结
Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels
1年前
已完结
Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity
1年前
已完结
Resistance of Lenvatinib in Hepatocellular Carcinoma
1年前
已完结
AXL Inhibitors: Status of Clinical Development
1年前
已完结
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
1年前
已完结
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
1年前
已完结
皖公网安备34019202002308
